Filip Krag Knop

Filip Krag Knop

Clinical Professor

Member of:

  • Internal Medicine: Endocrinology


Publication year:
All
21 - 30 out of 39Page size: 10
Sort by: 1st author
  1. Published

    Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial

    Hvistendahl, M. K., Naimi, R. M., Hansen, S. H., Rehfeld, Jens Frederik, Kissow, Hannelouise, Pedersen, Jens, Dragsted, Lars Ove, Sonne, D. P., Knop, Filip Krag & Jeppesen, Palle Bekker, 2022, In: Journal of Parenteral and Enteral Nutrition. 46, 4, p. 923-935 13 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes

    Hædersdal, S., Lund, A., Nielsen-Hannerup, E., Maagensen, H., Forman, Julie Lyng, Holst, Jens Juul, Knop, Filip Krag & Vilsbøll, Tina, 2022, In: European Journal of Endocrinology. 187, 4, p. 507-518 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    The Glucagon Receptor Antagonist LY2409021 has No Effect on Postprandial Glucose in Type 2 Diabetes

    Hædersdal, S., Lund, A., Maagensen, H., Nielsen-Hannerup, E., Gasbjerg, Lærke Smidt, Rosenkilde, Mette, Forman, Julie Lyng, van Hall, Gerrit, Holst, Jens Juul, Knop, Filip Krag & Vilsbøll, Tina, 2022, In: European Journal of Endocrinology. 186, 2, p. 207-221 15 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes

    Johansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, Camilla, Hartmann, Bolette, Holst, Jens Juul, Vilsbøll, Tina, Andersen, H. U. & Knop, Filip Krag, 2022, In: Diabetes, Obesity and Metabolism. 24, 2, p. 221-227

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Protocol for a 30-day randomised, parallel-group, non-inferiority, controlled trial investigating the effects of discontinuing renin-angiotensin system inhibitors in patients with and without COVID-19: The RASCOVID-19 trial

    Kliim-Hansen, V., Gasbjerg, Lærke Smidt, Ellegaard, A. M., Lorentsson, H. J. N., Lynggaard, M. B., Hagemann, C. A., Legart, C., Mathiesen, D. S., Sivapalan, P., Jensen , Jens-Ulrik Stæhr , Vilsbøll, Tina, Christensen, Mikkel Bring & Knop, Filip Krag, 2022, In: BMJ Open. 12, 11, e062895.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: A randomised, double-blind, active-comparator, non-inferiority clinical trial

    Kårhus, M. L., Brønden, A., Forman, Julie Lyng, Haaber, A., Knudsen, E., Langholz, Ebbe, Dragsted, Lars Ove, Hansen, S. H., Krakauer, M., Vilsbøll, Tina, Sonne, David Peick & Knop, Filip Krag, 2022, In: The Lancet Gastroenterology and Hepatology. 7, 10, p. 922-931 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Liraglutide versus colesevelam for treating bile acid diarrhoea – Authors' reply

    Kårhus, M. L. & Knop, Filip Krag, 2022, In: The Lancet Gastroenterology and Hepatology. 7, 12, p. 1075-1076 2 p.

    Research output: Contribution to journal › Comment/debate › Research › peer-review

  8. Published

    Enterohepatic, gluco-metabolic, and gut microbial characterization of individuals with bile acid malabsorption

    Kårhus, M. L., Sonne, David Peick, Thomasen, M., Ellegaard, A., Holst, Jens Juul, Rehfeld, Jens Frederik, Chávez-Talavera, O., Tailleux, A., Staels, B., Nielsen, Dennis Sandris, Dragsted, Lars Ove, Vilsbøll, Tina, Brønden, A. & Knop, Filip Krag, 2022, In: Gastro Hep Advances. 1, 3, p. 299-312 14 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Fibroblast growth factor 21 is the main alcohol responsive peptide hormone in humans and individuals with alcohol use disorder exihibit increased plasma concentrations after alcohol intake

    Lanng, A., Gasbjerg, Lærke Smidt, Sucksdorff, A., Svenningsen, J., Trammell, Sam, Vilsbøll, Tina, Gillum, M. & Knop, Filip Krag, 2022, In: Journal of Hepatology. 77, S1, p. S121-S121 1 p., THU006.

    Research output: Contribution to journal › Conference abstract in journal › Research

  10. Published

    THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

    Mathiesen, D. S., Lund, A., Holst, Jens Juul, Knop, Filip Krag, Lutz, T. A. & Bagger, J. I., 2022, In: European Journal of Endocrinology. 186, 6, p. R93-R111

    Research output: Contribution to journal › Review › Research › peer-review

Previous 1 2 3 4 Next

ID: 40100368